vs
American Bitcoin Corp.（ABTC）与Apellis Pharmaceuticals, Inc.（APLS）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是American Bitcoin Corp.的1.7倍（$199.9M vs $118.0M），American Bitcoin Corp.同比增速更快（151.5% vs -5.9%），过去两年American Bitcoin Corp.的营收复合增速更高（296.9% vs 7.7%）
美国比特币公司专注于比特币相关业务领域。比特币是首个去中心化加密货币，由化名为中本聪的匿名人士于2008年发布白皮书后诞生，2009年随着开源代码上线正式投入使用，问世以来对全球金融与数字货币领域都产生了极为深远的影响。
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
ABTC vs APLS — 直观对比
营收规模更大
APLS
是对方的1.7倍
$118.0M
营收增速更快
ABTC
高出157.4%
-5.9%
两年增速更快
ABTC
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $118.0M | $199.9M |
| 净利润 | — | $-59.0M |
| 毛利率 | 49.1% | — |
| 营业利润率 | -192.8% | -25.6% |
| 净利率 | — | -29.5% |
| 营收同比 | 151.5% | -5.9% |
| 净利润同比 | — | -62.2% |
| 每股收益（稀释后） | $-0.07 | $-0.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABTCAPLS
| Q4 25 | $118.0M | $199.9M | ||
| Q3 25 | $64.2M | $458.6M | ||
| Q2 25 | $1.4M | $178.5M | ||
| Q1 25 | $1.6M | $166.8M | ||
| Q4 24 | $46.9M | $212.5M | ||
| Q3 24 | $11.6M | $196.8M | ||
| Q2 24 | $5.5M | $199.7M | ||
| Q1 24 | $7.5M | $172.3M |
净利润ABTCAPLS
| Q4 25 | — | $-59.0M | ||
| Q3 25 | $3.5M | $215.7M | ||
| Q2 25 | $3.4M | $-42.2M | ||
| Q1 25 | $-100.6M | $-92.2M | ||
| Q4 24 | — | $-36.4M | ||
| Q3 24 | $-576.0K | $-57.4M | ||
| Q2 24 | $-61.1M | $-37.7M | ||
| Q1 24 | $230.4M | $-66.4M |
毛利率ABTCAPLS
| Q4 25 | 49.1% | — | ||
| Q3 25 | 56.0% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 57.9% | — | ||
| Q3 24 | 4.2% | — | ||
| Q2 24 | 31.0% | — | ||
| Q1 24 | 35.4% | — |
营业利润率ABTCAPLS
| Q4 25 | -192.8% | -25.6% | ||
| Q3 25 | 11.2% | 48.7% | ||
| Q2 25 | -162.1% | -18.6% | ||
| Q1 25 | -350.8% | -50.0% | ||
| Q4 24 | — | -12.3% | ||
| Q3 24 | -87.8% | -24.0% | ||
| Q2 24 | -106.4% | -14.7% | ||
| Q1 24 | -20.8% | -36.0% |
净利率ABTCAPLS
| Q4 25 | — | -29.5% | ||
| Q3 25 | 5.4% | 47.0% | ||
| Q2 25 | 249.2% | -23.6% | ||
| Q1 25 | -6458.5% | -55.3% | ||
| Q4 24 | — | -17.1% | ||
| Q3 24 | -5.0% | -29.2% | ||
| Q2 24 | -1107.2% | -18.9% | ||
| Q1 24 | 3076.2% | -38.5% |
每股收益（稀释后）ABTCAPLS
| Q4 25 | $-0.07 | $-0.40 | ||
| Q3 25 | $0.06 | $1.67 | ||
| Q2 25 | $-0.07 | $-0.33 | ||
| Q1 25 | $-0.09 | $-0.74 | ||
| Q4 24 | $1.10 | $-0.30 | ||
| Q3 24 | $-0.15 | $-0.46 | ||
| Q2 24 | $-0.10 | $-0.30 | ||
| Q1 24 | $-0.36 | $-0.54 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $466.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $665.8M | $370.1M |
| 总资产 | $1.2B | $1.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ABTCAPLS
| Q4 25 | — | $466.2M | ||
| Q3 25 | — | $479.2M | ||
| Q2 25 | $750.0K | $370.0M | ||
| Q1 25 | $367.0K | $358.4M | ||
| Q4 24 | $850.0K | $411.3M | ||
| Q3 24 | $478.0K | $396.9M | ||
| Q2 24 | $1.4M | $360.1M | ||
| Q1 24 | $1.9M | $325.9M |
总债务ABTCAPLS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $93.1M |
股东权益ABTCAPLS
| Q4 25 | $665.8M | $370.1M | ||
| Q3 25 | $575.5M | $401.2M | ||
| Q2 25 | $339.7M | $156.3M | ||
| Q1 25 | $115.8M | $164.2M | ||
| Q4 24 | $1.0B | $228.5M | ||
| Q3 24 | $697.5M | $237.1M | ||
| Q2 24 | $614.3M | $264.3M | ||
| Q1 24 | $696.8M | $266.7M |
总资产ABTCAPLS
| Q4 25 | $1.2B | $1.1B | ||
| Q3 25 | $1.2B | $1.1B | ||
| Q2 25 | $6.2M | $821.4M | ||
| Q1 25 | $9.0M | $807.3M | ||
| Q4 24 | $1.1B | $885.1M | ||
| Q3 24 | $7.5M | $901.9M | ||
| Q2 24 | $11.4M | $904.5M | ||
| Q1 24 | $17.8M | $831.9M |
负债/权益比ABTCAPLS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.35× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-79.6M | $-14.2M |
| 自由现金流经营现金流 - 资本支出 | — | $-14.3M |
| 自由现金流率自由现金流/营收 | — | -7.1% |
| 资本支出强度资本支出/营收 | — | 0.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $45.0M |
8季度趋势，按日历期对齐
经营现金流ABTCAPLS
| Q4 25 | $-79.6M | $-14.2M | ||
| Q3 25 | $-39.0M | $108.5M | ||
| Q2 25 | $-879.0K | $4.4M | ||
| Q1 25 | $-3.2M | $-53.4M | ||
| Q4 24 | $-54.0M | $19.4M | ||
| Q3 24 | $-76.8M | $34.1M | ||
| Q2 24 | $201.0K | $-8.3M | ||
| Q1 24 | $-983.0K | $-133.0M |
自由现金流ABTCAPLS
| Q4 25 | — | $-14.3M | ||
| Q3 25 | — | $108.3M | ||
| Q2 25 | $-1.4M | $4.4M | ||
| Q1 25 | — | $-53.4M | ||
| Q4 24 | $-60.6M | $19.3M | ||
| Q3 24 | $-79.3M | — | ||
| Q2 24 | $-874.0K | $-8.4M | ||
| Q1 24 | — | $-133.3M |
自由现金流率ABTCAPLS
| Q4 25 | — | -7.1% | ||
| Q3 25 | — | 23.6% | ||
| Q2 25 | -104.4% | 2.5% | ||
| Q1 25 | — | -32.0% | ||
| Q4 24 | -129.2% | 9.1% | ||
| Q3 24 | -683.2% | — | ||
| Q2 24 | -15.8% | -4.2% | ||
| Q1 24 | — | -77.3% |
资本支出强度ABTCAPLS
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | 40.5% | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | 14.1% | 0.0% | ||
| Q3 24 | 21.6% | 0.0% | ||
| Q2 24 | 19.5% | 0.0% | ||
| Q1 24 | — | 0.2% |
现金转化率ABTCAPLS
| Q4 25 | — | — | ||
| Q3 25 | -11.21× | 0.50× | ||
| Q2 25 | -0.26× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.00× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABTC
暂无分部数据
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
